Drug intelligence / Profile preview

[11C]NES

Development stage
Unknown
Lead developer
Uppsala University
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

[11C]NES (also known as [11C]GW457427) is a carbon-11 labeled small-molecule radiopharmaceutical that acts as a selective positron emission tomography (PET) imaging tracer for neutrophil elastase (NE). Originally derived from the small-molecule neutrophil elastase inhibitor GW457427 developed by GlaxoSmithKline, the radiotracer was developed and validated for clinical use by researchers at Uppsala University. [11C]NES is designed to non-invasively image and quantify neutrophil-mediated inflammation in vivo. It has been evaluated in clinical and preclinical studies for various inflammatory and oncology indications, including COVID-19-associated lung injury, acute respiratory distress syndrome (ARDS), rheumatoid arthritis, Type 1 diabetes, interstitial lung disease, and lung cancer.

Other names
11C-NEScarbon-11-GW457427carbon11-GW457427carbon 11-GW457427carbon-11-NEScarbon11-NEScarbon 11-NES
02

Targets

ELANE (Human Neutrophil Elastase)

Beyond the preview

Go deeper on [11C]NES.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [11C]NES.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call